Phaseline

Targets › MSLN

MSLN (Mesothelin): drug programs, companies and trials

19 programs from 11 companies in 33 trials: 32 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Dec 2026.

Membrane-anchored forms may play a role in cellular adhesion.; FUNCTION: Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro. (UniProt, Q13421)

Open in Phaseline: the race on MSLN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)Anetumab Ravtansine
Mesothelin binding agent; Tubulin inhibitor
MSLN, TubulinPhase 2Fallopian Tube Endometrioid Adenocarcinoma; Pancreatic Adenocarcinoma; Pleural Malignant MesotheliomaJan 2027
Chinese PLA General HospitalPan-T booster co-expressing MSLN CAR T cell
anti-MSLN CAR-T cell therapy with CD40 agonist and T cell costimulator agonist
MSLNPhase 1Advanced or Metastatic Solid TumorsDec 2026
Shenzhen University General HospitalMSLN CAR-T
Anti-MSLN chimeric antigen receptor T-cell therapy
MSLNPhase 1Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue)Jan 2027
Beijing BiotechEB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)
Allogeneic CAR-NK cells with dual-recognition CAR targeting MSLN and MUC1
MSLN, MUC1Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)Feb 2027
Beijing BiotechEB-G3B7-NK dual-target CAR-NK cells
Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr
CD276, MSLN, EGFR, ERBB2, IL13RA2Phase 1Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) …Feb 2027
Beijing BiotechEB-NK-MF CAR-NK cells
Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit
MSLN, FOLR1, MUC16, TROP2Phase 1Advanced Solid Tumors; Epithelial Ovarian CancerFeb 2027
Beijing BiotechEB-MF-CAR-NK-01
Dual-target CAR-NK cells recognizing mesothelin-positive tumor cells and FAP-positive stro
MSLN, FAPPhase 1Malignant Pleural MesotheliomasMar 2027
Beijing BiotechEB-CARMSLN-NK
Mesothelin-targeted allogeneic CAR-NK cells
MSLNPhase 1B2 ThymomaJun 2027
Memorial Sloan Kettering Cancer CenterMesothelin-targeted T cells
CAR-T cells targeting mesothelin
MSLNPhase 1Breast CancerJun 2027
Memorial Sloan Kettering Cancer CenterM28z1XXPD1DNR CAR T cells
Mesothelin-targeted CAR T cells with anti-PD1 component
MSLN, PDCD1Phase 1Malignant Pleural Mesothelioma (MPM); Mesothelin PositiveSep 2027
Essen BiotechMesothelin and Claudin 18.2 CAR-T cells
Dual-target CAR-T cells targeting Mesothelin and Claudin 18.2
MSLN, CLDN18Phase 1Pancreatic CancerDec 2027
Tianjin Medical University Cancer Institute and HospitalCHT102
mesothelin-targeting UCAR-T cells
MSLNPhase 1Advanced Pancreatic CancersDec 2027
A2 BiotherapeuticsA2B543
Mesothelin-targeting logic-gated CAR T cell therapy
MSLNPhase 1Solid Tumor, AdultJun 2028
A2 BiotherapeuticsA2B694
Mesothelin-targeting logic-gated CAR T cell therapy
MSLNPhase 1Solid Tumor, AdultJun 2028
Second Affiliated Hospital of Guangzhou Medical UniversityMesothelin/GPC3/GUCY2C-CAR-T cells
CAR-T cells targeting mesothelin, GPC3, and GUCY2C; second generation with IL-21/anti-PD-1
MSLN, GPC3, GUCY2CPhase 1Pancreas CancerMar 2029
Second Affiliated Hospital of Guangzhou Medical UniversityGPC3/Mesothelin-CAR-γδT cells
GPC3/Mesothelin-targeted CAR-γδT cell therapy
GPRC3, MSLNPhase 1Pancreas CancerNov 2030
National Cancer Institute (NCI)TNhYP218 CAR T Cells
anti-mesothelin CAR-T cell therapy
MSLNPhase 1MesotheliomaJun 2034
Context TherapeuticsCT-95
MSLN bispecific antibody
MSLNPhase 1Mesothelin-Expressing Tumors–
Zhongda HospitalTCR-like CAR-T
TCR-like CAR-T cell therapy targeting MSLN
MSLNPhase 1Safety and Efficacy of TCR-like CAR-T–

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC) (4) Pancreas Cancer (2) Epithelial Ovarian Cancer (2) Non-Small Cell Lung Cancer (2) Solid Tumor, Adult (2) Mesothelioma (1) Malignant Pleural Mesothelioma (MPM) (1) Mesothelin Positive (1) Advanced Solid Tumors (1) Fallopian Tube Endometrioid Adenocarcinoma (1) Pancreatic Adenocarcinoma (1) Pleural Malignant Mesothelioma (1)

Modalities

mixed (10), other (5), small molecule (2), protein or peptide (2)

Companies

Beijing Biotech (5) Second Affiliated Hospital of Guangzhou Medical University (2) National Cancer Institute (NCI) (2) Memorial Sloan Kettering Cancer Center (2) A2 Biotherapeutics (2) Chinese PLA General Hospital (1) Tianjin Medical University Cancer Institute and Hospital (1) Zhongda Hospital (1) Shenzhen University General Hospital (1) Essen Biotech (1) Context Therapeutics (1)

Related targets

GPRC3 (1) PDCD1 (1) FOLR1 (1) MUC16 (1) TROP2 (1) MUC1 (1) Tubulin (1) FAP (1) CD276 (1) EGFR (1) ERBB2 (1) IL13RA2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.